JP2018521086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521086A5 JP2018521086A5 JP2018503496A JP2018503496A JP2018521086A5 JP 2018521086 A5 JP2018521086 A5 JP 2018521086A5 JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018521086 A5 JP2018521086 A5 JP 2018521086A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- dextran sulfate
- use according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
| SE1551050-6 | 2015-07-30 | ||
| PCT/SE2016/050720 WO2017018922A1 (en) | 2015-07-30 | 2016-07-15 | New use of dextran sulfate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521086A JP2018521086A (ja) | 2018-08-02 |
| JP2018521086A5 true JP2018521086A5 (enExample) | 2018-09-13 |
| JP6837679B2 JP6837679B2 (ja) | 2021-03-03 |
Family
ID=57884849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503496A Active JP6837679B2 (ja) | 2015-07-30 | 2016-07-15 | 硫酸デキストランの新しい使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10478451B2 (enExample) |
| EP (1) | EP3328395B1 (enExample) |
| JP (1) | JP6837679B2 (enExample) |
| CN (2) | CN114712385A (enExample) |
| BR (1) | BR112018001942A2 (enExample) |
| DK (1) | DK3328395T3 (enExample) |
| EA (1) | EA034313B1 (enExample) |
| ES (1) | ES2882115T3 (enExample) |
| HK (1) | HK1246640A1 (enExample) |
| SE (1) | SE539575C2 (enExample) |
| WO (1) | WO2017018922A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212708A1 (en) * | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| EP3532072B1 (en) * | 2017-05-17 | 2020-01-01 | TX Medic AB | Treatment of glaucoma |
| JP2020533281A (ja) * | 2017-09-08 | 2020-11-19 | ティーエックス メディック エービー | デキストラン硫酸の新規使用 |
| CN111867647B (zh) * | 2018-03-09 | 2023-01-13 | 卡梅达股份公司 | 用于固定生物物质的方法的改进 |
| SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| JP2000507204A (ja) | 1995-12-18 | 2000-06-13 | ステイヒテイング・サンキン・ブロードボールジーニング | Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化 |
| US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| SE525461C3 (sv) * | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| WO2007028053A2 (en) * | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| WO2007075388A2 (en) * | 2005-12-15 | 2007-07-05 | X-Cell Medical Incorporated | Methods of locally treating and preventing cardiac disorders |
| WO2008134430A1 (en) * | 2007-04-24 | 2008-11-06 | Novelmed Therapeutics Inc. | Methods and compositions of inhibiting complement and cellular activation with dextran sulfate |
| WO2011091167A2 (en) * | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| EP2768522B1 (en) * | 2011-10-18 | 2016-07-27 | CSL Behring GmbH | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| CN102973593A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗肝纤维化药物中的应用 |
| WO2015190989A1 (en) | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
| HRP20190051T1 (hr) * | 2014-06-12 | 2019-03-08 | Tx Medic Ab | Uporaba dekstran sulfata koji ima prosječnu molekularnu masu ispod 10000 da za induciranje angiogeneze kod subjekta |
-
2015
- 2015-07-30 SE SE1551050A patent/SE539575C2/en unknown
-
2016
- 2016-07-15 EP EP16830923.5A patent/EP3328395B1/en active Active
- 2016-07-15 HK HK18106000.5A patent/HK1246640A1/zh unknown
- 2016-07-15 JP JP2018503496A patent/JP6837679B2/ja active Active
- 2016-07-15 DK DK16830923.5T patent/DK3328395T3/da active
- 2016-07-15 US US15/748,519 patent/US10478451B2/en active Active
- 2016-07-15 EA EA201890212A patent/EA034313B1/ru not_active IP Right Cessation
- 2016-07-15 ES ES16830923T patent/ES2882115T3/es active Active
- 2016-07-15 BR BR112018001942A patent/BR112018001942A2/pt not_active Application Discontinuation
- 2016-07-15 CN CN202210555037.5A patent/CN114712385A/zh active Pending
- 2016-07-15 CN CN201680044788.3A patent/CN107921055A/zh active Pending
- 2016-07-15 WO PCT/SE2016/050720 patent/WO2017018922A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521086A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2011528333A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| JP2012041342A5 (enExample) | ||
| JP2011225596A5 (enExample) | ||
| JP2014077003A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2016517421A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| WO2007087241A3 (en) | Treatment of ischemic disease using thrombopoietin | |
| JP2015502389A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| JP2014139255A5 (enExample) | ||
| JP2015517994A5 (enExample) | ||
| JP2016517401A5 (enExample) | ||
| JP2019529570A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| ES2924728T3 (es) | Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas | |
| JP2012525358A5 (enExample) |